Baylor College of Medicine
Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy(Baylor College of Medicine)은 Leukemia, B-Cell 표적 세포·유전자 치료로, Leukemia, B-Cell 영역에서 개발·상용화 중입니다. 작용기전: targeting aberrant cell-surface antigen. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I tr.
Leukemia, B-Cell
Leukemia, B-Cell
Recruiting
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
retrovirally transduced with MAGE-A3 TCR plus systemic high-dose IL-2
novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I tr
targeting aberrant cell-surface antigen
cytokine release syndrome, capillary leak syndrome, neurotoxicity, autoimmune sequelae, and cardiac dysfunction
biomarkers exist to predict toxicity risk, underscoring the need for further research
escape relapse in DLBCL
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Baylor College of Medicine
Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy(Baylor College of Medicine)은 Leukemia, B-Cell 표적 세포·유전자 치료로, Leukemia, B-Cell 영역에서 개발·상용화 중입니다. 작용기전: targeting aberrant cell-surface antigen. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I tr.
Leukemia, B-Cell
Leukemia, B-Cell
Recruiting
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
retrovirally transduced with MAGE-A3 TCR plus systemic high-dose IL-2
novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I tr
targeting aberrant cell-surface antigen
cytokine release syndrome, capillary leak syndrome, neurotoxicity, autoimmune sequelae, and cardiac dysfunction
biomarkers exist to predict toxicity risk, underscoring the need for further research
escape relapse in DLBCL
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.